Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
Official title: An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2025-03-13
Completion Date
2027-12
Last Updated
2025-03-24
Healthy Volunteers
No
Conditions
Interventions
SHR-A1811
SHR-A1811.
Paclitaxel Injection
Paclitaxel Injection.
Doxorubicin Hydrochloride Liposome Injection
Doxorubicin Hydrochloride Liposome Injection.
Gemcitabine Hydrochloride for Injection
Gemcitabine Hydrochloride for Injection.
Topotecan Hydrochloride for Injection
Topotecan Hydrochloride for Injection.
Locations (2)
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Qilu Hospital of Shandong University
Jinan, Shandong, China